Adi Reich1, Alison S Bae, Aileen M Barnes, Wayne A Cabral, Aleksander Hinek, Jennifer Stimec, Suvimol C Hill, David Chitayat, Joan C Marini. 1. Bone and Extracellular Matrix Branch (A.R., A.S.B., A.M.B., W.A.C., J.C.M.), Eunice Kennedy Shriver National Institute of Child Health and Human Development, and Department of Diagnostic Radiology (S.C.H.), National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, Maryland 20892; Physiology and Experimental Medicine Program (A.H.), Heart Center, Hospital for Sick Children, University of Toronto, Ontario, Canada M5S 3OA4; Division of Diagnostic Imaging (J.S.), Department of Pediatrics, and Division of Clinical and Metabolic Genetics (D.C.), Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada M5G 1X8; and The Prenatal Diagnosis and Medical Genetics Program (D.C.), Department of Obstetrics and Gynecology, Mt Sinai Hospital, University of Toronto, Toronto, Ontario, Canada M5G 1Z5.
Abstract
CONTEXT: Patients with type V osteogenesis imperfecta (OI) are heterozygous for a dominant IFITM5 c.-14C>T mutation, which adds five residues to the N terminus of bone-restricted interferon-induced transmembrane-like protein (BRIL), a transmembrane protein expressed in osteoblasts. Type V OI skeletal findings include hyperplastic callus formation, ossification of the forearm interosseous membrane, and dense metaphyseal bands. OBJECTIVE: The objective of this study was to examine the role of osteoblasts in the active mineralization traits of type V OI and the effect of the IFITM5 mutation on type I collagen. METHODS: We identified eight patients with the IFITM5 c.-14C>T mutation. Cultured osteoblasts from type V OI patients were used to study osteoblast differentiation and mineralization. RESULTS: We verified the expression and stability of mutant IFITM5 transcripts. In differentiated type V OI primary osteoblasts in culture, the IFITM5 expression and BRIL level is comparable with control. Both early and late markers of osteoblast differentiation are increased in type V OI osteoblasts. Mineralization, assayed by alizarin red staining, was increased in type V OI osteoblasts compared with control. However, type V OI osteoblasts have significantly decreased COL1A1 transcripts in mid- to late differentiation. Type I collagen protein is concomitantly decreased, with decreased cross-linked collagen in matrix and altered appearance of fibrils deposited in culture. CONCLUSIONS: This study demonstrates that type V OI mineralization has a gain-of-function mechanism at the osteoblast level, which likely underlies the overactive tissue mineralization seen in patients. Decreased type I collagen expression, secretion, and matrix incorporation establish type V OI as a collagen-related defect.
CONTEXT: Patients with type V osteogenesis imperfecta (OI) are heterozygous for a dominant IFITM5 c.-14C>T mutation, which adds five residues to the N terminus of bone-restricted interferon-induced transmembrane-like protein (BRIL), a transmembrane protein expressed in osteoblasts. Type V OI skeletal findings include hyperplastic callus formation, ossification of the forearm interosseous membrane, and dense metaphyseal bands. OBJECTIVE: The objective of this study was to examine the role of osteoblasts in the active mineralization traits of type V OI and the effect of the IFITM5 mutation on type I collagen. METHODS: We identified eight patients with the IFITM5 c.-14C>T mutation. Cultured osteoblasts from type V OI patients were used to study osteoblast differentiation and mineralization. RESULTS: We verified the expression and stability of mutant IFITM5 transcripts. In differentiated type V OI primary osteoblasts in culture, the IFITM5 expression and BRIL level is comparable with control. Both early and late markers of osteoblast differentiation are increased in type V OI osteoblasts. Mineralization, assayed by alizarin red staining, was increased in type V OI osteoblasts compared with control. However, type V OI osteoblasts have significantly decreased COL1A1 transcripts in mid- to late differentiation. Type I collagen protein is concomitantly decreased, with decreased cross-linked collagen in matrix and altered appearance of fibrils deposited in culture. CONCLUSIONS: This study demonstrates that type V OI mineralization has a gain-of-function mechanism at the osteoblast level, which likely underlies the overactive tissue mineralization seen in patients. Decreased type I collagen expression, secretion, and matrix incorporation establish type V OI as a collagen-related defect.
Authors: Wayne A Cabral; Weizhong Chang; Aileen M Barnes; MaryAnn Weis; Melissa A Scott; Sergey Leikin; Elena Makareeva; Natalia V Kuznetsova; Kenneth N Rosenbaum; Cynthia J Tifft; Dorothy I Bulas; Chahira Kozma; Peter A Smith; David R Eyre; Joan C Marini Journal: Nat Genet Date: 2007-02-04 Impact factor: 38.330
Authors: Pierre Moffatt; Marie-Helene Gaumond; Patrick Salois; Karine Sellin; Marie-Claude Bessette; Eric Godin; Paulo Tambasco de Oliveira; Gerald J Atkins; Antonio Nanci; Gethin Thomas Journal: J Bone Miner Res Date: 2008-09 Impact factor: 6.741
Authors: Wayne A Cabral; Elena Makareeva; Alain Colige; Anne D Letocha; Jennifer M Ty; Heather N Yeowell; Gerard Pals; Sergey Leikin; Joan C Marini Journal: J Biol Chem Date: 2005-02-22 Impact factor: 5.157
Authors: Aileen M Barnes; Weizhong Chang; Roy Morello; Wayne A Cabral; MaryAnn Weis; David R Eyre; Sergey Leikin; Elena Makareeva; Natalia Kuznetsova; Thomas E Uveges; Aarthi Ashok; Armando W Flor; John J Mulvihill; Patrick L Wilson; Usha T Sundaram; Brendan Lee; Joan C Marini Journal: N Engl J Med Date: 2006-12-28 Impact factor: 91.245
Authors: F H Glorieux; F Rauch; H Plotkin; L Ward; R Travers; P Roughley; L Lalic; D F Glorieux; F Fassier; N J Bishop Journal: J Bone Miner Res Date: 2000-09 Impact factor: 6.741
Authors: Alexa Patoine; Marie-Hélène Gaumond; Prashant K Jaiswal; François Fassier; Frank Rauch; Pierre Moffatt Journal: J Bone Miner Res Date: 2014-09 Impact factor: 6.741
Authors: Joan C Marini; Antonella Forlino; Wayne A Cabral; Aileen M Barnes; James D San Antonio; Sarah Milgrom; James C Hyland; Jarmo Körkkö; Darwin J Prockop; Anne De Paepe; Paul Coucke; Sofie Symoens; Francis H Glorieux; Peter J Roughley; Alan M Lund; Kaija Kuurila-Svahn; Heini Hartikka; Daniel H Cohn; Deborah Krakow; Monica Mottes; Ulrike Schwarze; Diana Chen; Kathleen Yang; Christine Kuslich; James Troendle; Raymond Dalgleish; Peter H Byers Journal: Hum Mutat Date: 2007-03 Impact factor: 4.878
Authors: Stéphane Blouin; Nadja Fratzl-Zelman; Francis H Glorieux; Paul Roschger; Klaus Klaushofer; Joan C Marini; Frank Rauch Journal: J Bone Miner Res Date: 2017-06-26 Impact factor: 6.741
Authors: Evelise Brizola; Eduardo P Mattos; Jessica Ferrari; Patricia O A Freire; Raquel Germer; Juan C Llerena; Têmis M Félix Journal: Mol Syndromol Date: 2015-09-03